These clinical trials do not use chemotherapy, such as cladribine or pentostatin. Instead, they focus on treatments like Vemurafenib, Binimetinib, Rituximab, and newer options such as CAR-T cell therapy.

Venetoclax for People With Relapsed HCL

Learn more about this trial (link to trial here)

What is the primary objective of this clinical trial?

To determine the objective response rate (ORR) of venetoclax in patients with HCL that has returned after improvement.

Venetoclax belongs to a group of drugs called B-cell lymphoma-2 (BCL-2) inhibitors. It stops cancer cells from growing by blocking BCL-2, a protein that cancer cells need to survive. Venetoclax comes in a tablet form.

ORR is the percentage of people in a study who have a partial or complete response to treatment within a certain period. A partial response is a decrease in tumor size or cancer amount, and a complete response is the disappearance of all cancer signs. Measuring ORR in a clinical trial shows how well a new treatment works.

You may be able to join this trial if you:

• Have relapsed hairy cell leukemia (HCL) or relapsed HCL variant (HCLv)

• Have previously received purine analog treatment

• Were treated using BRAF inhibitors, but relapsed, or are ineligible for BRAF inhibitors

• Have not previously been treated with venetoclax

• Need treatment because your disease is active

• Meet the study’s other lab and health requirements

Who to contact about this trial:

This study has 21 locations, including sites in California, Florida, Kansas, Missouri, and Maryland.

Robert J Kreitman from the NCI is the Principal Investigator.

Phone: 800-411-1222

…

Binimetinib as a treatment for people with relapsed or refractory BRAF wild-type hairy cell leukemia (HCL) and HCL variant (HCLv)

Learn more about this trial. (link to trial here)

What is the primary objective of this clinical trial?

To see if binimetinib is an effective treatment for people with HCL that does not have a BRAF mutation.

Most people with HCL have a BRAF gene mutation. They can be treated with BRAF inhibitors, drugs that target this mutation. For people who do not have this mutation, BRAF inhibitors are not a treatment option. The researchers found that when HCL does not have the BRAF mutation, the MEK gene is frequently mutated. Binimetinib targets MEK.

You may be able to join this trial if you:

• Have BRAF wild-type HCL or HCLv

• Do not have the BRAF mutation

• Have received at least one prior treatment with a purine analog, such as cladribine or pentostatin

• Need treatment, as shown by blood counts or an enlarged spleen

• Do not have an uncontrolled infection, heart or lung problems, or another cancer that needs treatment

• Have not received any treatment in the 4 weeks before the study begins

• Meet the study’s other lab and health requirements.

Who to contact about this trial:

Holly M Eager, R.N.; (240) 858-7229; holly.eager@nih.gov

…

Phase I Study of Anti-CD22 CAR T-Cell Therapy for Patients with Relapsed or Refractory Hairy Cell Leukemia (HCL) and HCL Variant (HCLv)

Learn more about this trial. (link to trial here)

What is the primary objective of this clinical trial?

To see if anti-CD22 CAR T-cells are safe and effective for people with HCL or HCLv after they have received a treatment regimen of cyclophosphamide and fludarabine.

CAR (Chimeric Antigen Receptor) T-cell therapy is a type of cancer treatment in which a person’s T cells (a type of immune cell) are changed in a laboratory to recognize and attack cancer cells. 

You may be able to join this trial if you:

• Have HCL or HCLv

• Have previously received treatment with or been ineligible for: 1) Chemotherapy combined with Rituximab, 2) moxetumomab pasudotox, and/or 3) a BRAF inhibitor such as Vemurafenib.

• Need treatment

• Meet the study’s other lab and health requirements.

Who to contact about this trial:

This study has one location.

National Institutes of Health

Olena Sierra: (240) 858-3185 or olena.sierraortiz@nih.gov

…

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/​Refractory HCL

Learn more about this trial. (link to trial here)

What is the primary objective of this clinical trial?

To test whether treating BRAF-positive HCL with both encorafenib and binimetinib works better than vemurafenib alone.

Encorafenib is a medicine often given with other drugs, like binimetinib, to treat some cancers. It works by blocking proteins made by the mutated BRAF gene. It comes in a capsule form.

Binimetinib is a medicine that blocks proteins called MEK1 and MEK2. It comes in a tablet form.

You may be able to join this trial if you:

• Have BRAF-positive HCL that did not respond to treatment or has returned after treatment

• Have had at least one previous purine analog treatment, such as cladribine or pentostatin

• Need treatment

• Meet the study’s other lab and health requirements.

Who to contact about this trial:

This study has one location.

Dr. Robert J. Kreitman

kreitmar@mail.nih.gov or 301-648-7375

Holly M Eager, R.N.

holly.eager@nih.gov or (240) 858-7229

A randomized clinical trial is a study in which participants are assigned randomly to different treatment groups to compare outcomes.

Vemurafenib plus Obinutuzumab Vs. Cladribine plus Rituximab in Previously Untreated HCL

Learn more about this trial. (link to trial here)

View the webinar about this study.>>

What is the primary objective of this clinical trial?

Study the safety of vemurafenib in combination with obinutuzumab compared to the standard approach of cladribine in combination with rituximab.

The researchers will examine which treatment causes fewer or milder side effects and which approach is more effective at eliminating cancer cells.

Vemurafenib is a drug that blocks proteins produced by the BRAF V600E mutation.

Obinutuzumab is a medicine used in combination with other drugs to treat certain types of cancer. Obinutuzumab binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of leukemia and lymphoma cells. Obinutuzumab blocks CD20 and helps the immune system kill cancer cells. It is a type of monoclonal antibody.

Patients enrolling in this trial will receive one of two treatment options, both of which are effective in treating classic BRAF-positive HCL. No placebo is involved in this trial.

You may be able to join this trial if you:

• Have HCL

• Have the BRAF V600E mutation; if unsure, repeat BRAF testing.

• Have not received any prior therapy for HCL

• Need treatment

• Meet the study’s other lab and health requirements.

Who to contact about this trial:

Jae Park, MD   Email: parkj6@mskcc.org

Study back-up contact: Mark Geyer, MD   Phone Number: 646-608-3745

Chemotherapy for HCL uses drugs called purine analogs, like Cladribine and Pentostatin.

Cladribine and Rituximab in Treating Patients with Hairy Cell Leukemia

Learn more about this trial. (link to trial here)

What are the primary objectives of this clinical trial?

To study the combination of cladribine followed by rituximab in people with HCL, and

Determine how effective this approach is at achieving complete remission, eliminating minimal residual disease (MRD), and improving long-term outcomes.

You may be able to join this trial if you have:

• Have HCL

• If relapsed, have had no more than one prior treatment

• Meet the study’s other lab and health requirements.

Who to contact about this trial:

Farhad Ravandi, MD

Phone: 713-792-7305 or Email: fravandi@mdanderson.org

Vemurafenib plus Obinutuzumab Vs. Cladribine plus Rituximab in Previously Untreated HCL

Learn more about this clinical trial. (link to trial here)

View the webinar about this study.>>

What is the primary objective of this clinical trial?

Study the safety of vemurafenib in combination with obinutuzumab compared to the standard approach of cladribine in combination with rituximab.

The researchers will examine which treatment causes fewer or milder side effects and which approach is more effective at eliminating cancer cells.

Vemurafenib is a drug that blocks proteins produced by the BRAF V600E mutation.

Obinutuzumab is a medicine used in combination with other drugs to treat certain types of cancer. Obinutuzumab binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of leukemia and lymphoma cells. Obinutuzumab blocks CD20 and helps the immune system kill cancer cells. It is a type of monoclonal antibody.

You may be able to join this trial if you:

• Have HCL

• Have the BRAF V600E mutation; if unsure, repeat BRAF testing.

• Have not received any prior therapy for HCL

• Need treatment

• Meet the study’s other lab and health requirements.

Who to contact about this trial:

Jae Park, MD   Email: parkj6@mskcc.org

Study back-up contact: Mark Geyer, MD   Phone Number: 646-608-3745

…

Cladribine and Rituximab in Treating Patients with Hairy Cell Leukemia

Learn more about this trial. (link to trial here)

What are the primary objectives of this clinical trial?

To study the combination of cladribine followed by rituximab in people with HCL, and

Determine how effective this approach is at achieving complete remission, eliminating minimal residual disease (MRD), and improving long-term outcomes.

You may be able to join this trial if you:

• Have HCL

• If relapsed, have had no more than one prior treatment

Who to contact about this trial:

Farhad Ravandi, MD

Phone: 713-792-7305 or Email: fravandi@mdanderson.org

Venetoclax for People With Relapsed HCL

Learn more about this trial (link to trial here)

What is the primary objective of this clinical trial?

To determine the objective response rate (ORR) of venetoclax in patients with HCL that has returned after improvement.

Venetoclax belongs to a group of drugs called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop cancer cells from growing by blocking BCL-2, a protein that cancer cells need to survive.

ORR is the percentage of people in a study who have a partial or complete response to treatment within a certain period. A partial response is a decrease in tumor size or cancer amount, and a complete response is the disappearance of all cancer signs. Measuring ORR in a clinical trial shows how well a new treatment works.

You may be able to take part in this trial if you:

• Have relapsed hairy cell leukemia (HCL) or relapsed HCL variant (HCLv)

• Have previously received purine analog treatment

• Were treated using BRAF inhibitors, but relapsed, or are ineligible for BRAF inhibitors

• Have not previously been treated with venetoclax

• Need treatment because your disease is active

• Meet the study’s other lab and health requirements

Who to contact about this trial:

This study has 21 locations, including sites in California, Florida, Kansas, Missouri, and Maryland.

Robert J Kreitman from the NCI is the Principal Investigator.

Phone: 800-411-1222

…

Tovorafenib + rituximab in recurrent/refractory classic HCL and comparing with cladribine + rituximab in untreated classic HCL.

Learn more about this trial. (link to trial here)

What are the primary objectives of this clinical trial?

To evaluate the safety and tolerability of tovorafenib plus rituximab in patients with relapsed or refractory HCL, and 

To determine the MRD-negative complete remission rate of tovorafenib plus rituximab compared to cladribine plus rituximab for untreated HCL.

Tovorafenib is a drug used to treat pediatric cancer that is being studied in other types of cancer, including HCL. Tovorafenib blocks certain proteins made by the mutated BRAF gene.

Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some cancer cells.

You may be able to join this trial if you:

• Have BRAF-positive HCL

• Have had prior therapy with at least one purine analog (fludarabine, pentostatin, or cladribine) unless you are ineligible.

• Need treatment

• Meet the study’s other lab and health requirements.

Who to contact about this trial:

This study has 4 locations, including sites in Maryland, Ohio, Pennsylvania, and Virginia.

The principal investigator for this trial is Seema A. Bhat, The Ohio State University Comprehensive Cancer Center. 

Phone number: 800-293-5066

Email address: Jamesline@osumc.edu

…

Phase I Study of Anti-CD22 CAR T-Cell Therapy for Patients with Relapsed or Refractory Hairy Cell Leukemia (HCL) And HCL Variant (HCLv)

Learn more about this trial. (link to trial here)

What is the primary objective of this clinical trial?

To see if anti-CD22 CAR T-cells are safe and effective for people with HCL or HCLv after they have received a treatment regimen of cyclophosphamide and fludarabine.

CAR (Chimeric Antigen Receptor) T-cell therapy is a type of cancer treatment in which a person’s T cells (a type of immune cell) are changed in a laboratory to recognize and attack cancer cells. 

You may be able to join this trial if you:

• Have HCL or HCLv

• Have previously received treatment or been ineligible for: 1) Chemotherapy combined with Rituximab, 2) moxetumomab pasudotox, and/or 3) a BRAF inhibitor such as Vemurafenib.

• Need treatment

• Meet the study’s other lab and health requirements.

Who to contact about this trial:

This study has one location.

Olena Sierra: (240) 858-3185 or olena.sierraortiz@nih.gov

…

Encorafenib plus Binimetinib is being studied for people with BRAF V600E-mutated relapsed or refractory Hairy Cell Leukemia (HCL).

Learn more about this trial. (link to trial here)

What is the primary objective of this clinical trial?

This trial is testing whether treating BRAF-positive HCL with both encorafenib and binimetinib works better than vemurafenib alone.

Encorafenib is a medicine often given with other drugs, like binimetinib, to treat some cancers. It works by blocking proteins made by the mutated BRAF gene. It comes in a capsule form.

Binimetinib is a medicine that blocks proteins called MEK1 and MEK2. It comes in a tablet form.

You may be able to join this trial if you:

• Have BRAF-positive HCL that did not respond to treatment or has returned after treatment

• Have had at least one previous purine analog treatment, such as cladribine or pentostatin

• Currently need treatment

• Do not have an uncontrolled infection, serious heart or lung problems, or another cancer that also needs treatment

• Have not received any treatment in the four weeks before the study starts

Who to contact about this trial:

This study has one location.

Dr. Robert J. Kreitman

kreitmar@mail.nih.gov or 301-648-7375

Holly M Eager, R.N.

holly.eager@nih.gov or (240) 858-7229

…

Binimetinib for people with relapsed/refractory BRAF Wild Type HCL and Variant

Learn more about this trial. (link to trial here)

What is the primary objective of this clinical trial?

To see if binimetinib is an effective treatment for people with HCL that does not have a BRAF mutation.

Most people with HCL have a BRAF gene mutation. They can be treated with BRAF inhibitors, drugs that target this mutation. For people who do not have this mutation, BRAF inhibitors are not a treatment option. The researchers found that when HCL does not have the BRAF mutation, the MEK gene is frequently mutated. Binimetinib targets MEK.

You may be able to join this trial if you:

• Have BRAF wild-type HCL or HCLv

• Do not have the BRAF mutation

• Have received at least one prior treatment with a purine analog, such as cladribine or pentostatin

• Need treatment, as shown by blood counts or an enlarged spleen

• Do not have an uncontrolled infection, heart or lung problems, or another cancer that needs treatment

• Have not received any treatment in the 4 weeks before the study begins

• Meet the study’s other lab and health requirements.

Who to contact about this trial:

Holly M Eager, R.N.; (240) 858-7229; holly.eager@nih.gov

…

Cladribine and Rituximab in Treating Patients with Hairy Cell Leukemia

Learn more about this trial. (link to trial here)

What are the primary objectives of this clinical trial?

To study the combination of cladribine followed by rituximab in people with HCL, and

Determine how effective this approach is at achieving complete remission, eliminating minimal residual disease (MRD), and improving long-term outcomes.

You may be able to join this trial if you have:

• Have HCL

• If relapsed, have had no more than one prior treatment

Who to contact about this trial:

Farhad Ravandi, MD

Phone: 713-792-7305 or Email: fravandi@mdanderson.org

Venetoclax for People With Relapsed HCL

Learn more about this trial (link to trial here)

What is the primary objective of this clinical trial?

To determine the objective response rate (ORR) of venetoclax in patients with HCL that has returned after improvement.

Venetoclax belongs to a group of drugs called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop cancer cells from growing by blocking BCL-2, a protein that cancer cells need to survive. Venetoclax comes in a tablet form.

ORR is the percentage of people in a study who have a partial or complete response to treatment within a certain period. A partial response is a decrease in tumor size or cancer amount, and a complete response is the disappearance of all cancer signs. Measuring ORR in a clinical trial shows how well a new treatment works.

You may be able to join this trial if you:

• Have relapsed hairy cell leukemia (HCL) or relapsed HCL variant (HCLv)

• Have previously received purine analog treatment

• Were treated using BRAF inhibitors, but relapsed, or are ineligible for BRAF inhibitors

• Have not previously been treated with venetoclax

• Need treatment because your disease is active

• Meet the study’s other lab and health requirements

Who to contact about this trial:

This study has 21 locations, including sites in California, Florida, Kansas, Missouri, and Maryland.

Robert J Kreitman from the NCI is the Principal Investigator.

Phone: 800-411-1222

…

Tovorafenib + rituximab in recurrent/refractory classic HCL and comparing with cladribine + rituximab in untreated classic HCL

Learn more about this trial. (link to trial here)

What are the primary objectives of this clinical trial?

To evaluate the safety and tolerability of tovorafenib plus rituximab in patients with relapsed or refractory HCL, and 

To determine the MRD-negative complete remission rate of tovorafenib plus rituximab compared to cladribine plus rituximab for untreated HCL.

Tovorafenib is a drug used to treat pediatric cancer that is being studied in other types of cancer, including HCL. Tovorafenib blocks certain proteins made by the mutated BRAF gene.

Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some cancer cells.

You may be eligible to join this trial if you:

• Have BRAF-positive HCL

• Have had prior therapy with at least one purine analog (fludarabine, pentostatin, or cladribine) unless you are ineligible.

• Need treatment

• Meet the study’s other lab and health requirements.

Who to contact about this trial:

This study has 4 locations, including sites in Maryland, Ohio, Pennsylvania, and Virginia.

The principal investigator for this trial is Seema A. Bhat, The Ohio State University Comprehensive Cancer Center. 

Phone number: 800-293-5066

Email address: Jamesline@osumc.edu

…

Vemurafenib plus Obinutuzumab Vs. Cladribine plus Rituximab in Previously Untreated HCL

Learn more about this trial. (link to trial here)

View the webinar about this study.>>

What is the primary objective of this clinical trial?

Study the safety of vemurafenib in combination with obinutuzumab compared to the standard approach of cladribine in combination with rituximab.

The researchers will examine which treatment causes fewer or milder side effects and which approach is more effective at eliminating cancer cells.

Vemurafenib is a drug that blocks proteins produced by the BRAF V600E mutation.

Obinutuzumab is a medicine used in combination with other drugs to treat certain types of cancer. Obinutuzumab binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of leukemia and lymphoma cells. Obinutuzumab blocks CD20 and helps the immune system kill cancer cells. It is a type of monoclonal antibody.

You may be able to join this trial if you:

• Have classical HCL

• Have the BRAF V600E mutation; if unsure, repeat BRAF testing.

• Have not received any prior therapy for HCL

• Need treatment

• Meet the study’s other lab and health requirements.

Who to contact about this trial:

Jae Park, MD   Email: parkj6@mskcc.org

Study back-up contact: Mark Geyer, MD   Phone Number: 646-608-3745

…

Phase I Study of Anti-CD22 CAR T-Cell Therapy for Patients with Relapsed or Refractory Hairy Cell Leukemia (HCL) And HCL Variant (HCLv)

Learn more about this trial. (link to trial here)

What is the primary objective of this clinical trial?

To see if anti-CD22 CAR T-cells are safe and effective for people with HCL or HCLv after they have received a treatment regimen of cyclophosphamide and fludarabine.

CAR (Chimeric Antigen Receptor) T-cell therapy is a type of cancer treatment in which a person’s T cells (a type of immune cell) are changed in a laboratory to recognize and attack cancer cells. 

You may be able to join this trial if you:

• Have HCL or HCLv

• Have previously received treatment or been ineligible for: 1) Chemotherapy combined with Rituximab, 2) moxetumomab pasudotox, and/or 3) a BRAF inhibitor such as Vemurafenib.

• Need treatment

• Meet the study’s other lab and health requirements.

Who to contact about this trial:

This study has one location.

Olena Sierra: (240) 858-3185 or olena.sierraortiz@nih.gov

…

Encorafenib plus Binimetinib is being studied for people with BRAF V600E-mutated relapsed or refractory Hairy Cell Leukemia (HCL).

Learn more about this trial. (link to trial here)

What is the primary objective of this clinical trial?

This trial is testing whether treating BRAF-positive HCL with both encorafenib and binimetinib works better than vemurafenib alone.

Encorafenib is a medicine often given with other drugs, like binimetinib, to treat some cancers. It works by blocking proteins made by the mutated BRAF gene. It comes in a capsule form.

Binimetinib is a medicine that blocks proteins called MEK1 and MEK2. It comes in a tablet form.

You may be eligible to join this trial if you:

• Have BRAF-positive HCL that did not respond to treatment or has returned after treatment

• Have had at least one previous purine analog treatment, such as cladribine or pentostatin

• Currently need treatment

• Do not have an uncontrolled infection, serious heart or lung problems, or another cancer that also needs treatment

• Have not received any treatment in the four weeks before the study starts

Who to contact about this trial:

This study has one location.

Dr. Robert J. Kreitman

kreitmar@mail.nih.gov or 301-648-7375

Holly M Eager, R.N.

holly.eager@nih.gov or (240) 858-7229

…

Cladribine and Rituximab in Treating Patients with Hairy Cell Leukemia

Learn more about this trial. (link to trial here)

What are the primary objectives of this clinical trial?

To study the combination of cladribine followed by rituximab in people with HCL, and

Determine how effective this approach is at achieving complete remission, eliminating minimal residual disease (MRD), and improving long-term outcomes.

You may be able to join this trial if you:

• Have HCL

• If relapsed, have had no more than one prior treatment

Who to contact about this trial:

Farhad Ravandi, MD

Phone: 713-792-7305 or Email: fravandi@mdanderson.org

Venetoclax for People With Relapsed HCL

Learn more about this trial (link to trial here)

What is the primary objective of this clinical trial?

To determine the objective response rate (ORR) of venetoclax in patients with HCL that has returned after improvement.

Venetoclax belongs to a group of drugs called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop cancer cells from growing by blocking BCL-2, a protein that cancer cells need to survive. It comes in a tablet form.

ORR is the percentage of people in a study who have a partial or complete response to treatment within a certain period. A partial response is a decrease in tumor size or cancer amount, and a complete response is the disappearance of all cancer signs. Measuring ORR in a clinical trial shows how well a new treatment works.

You may be able to join this trial if you:

• Have relapsed hairy cell leukemia (HCL) or relapsed HCL variant (HCLv)

• Have previously received purine analog treatment

• Were treated using BRAF inhibitors, but relapsed, or are ineligible for BRAF inhibitors

• Have not previously been treated with venetoclax

• Need treatment because your disease is active

• Meet the study’s other lab and health requirements

Who to contact about this trial:

This study has 21 locations, including sites in California, Florida, Kansas, Missouri, and Maryland.

Robert J Kreitman from the NCI is the Principal Investigator.

Phone: 800-411-1222

…

Binimetinib for people with relapsed/refractory BRAF Wild Type HCL and Variant

Learn more about this trial. (link to trial here)

What is the primary objective of this clinical trial?

To see if binimetinib is an effective treatment for people with HCL that does not have a BRAF mutation.

Most people with HCL have a BRAF gene mutation. They can be treated with BRAF inhibitors, drugs that target this mutation. For people who do not have this mutation, BRAF inhibitors are not a treatment option. The researchers found that when HCL does not have the BRAF mutation, the MEK gene is frequently mutated. Binimetinib targets MEK.

You may be able to join this trial if you:

• Have BRAF wild-type HCL or HCLv

• Do not have the BRAF mutation

• Have received at least one prior treatment with a purine analog, such as cladribine or pentostatin

• Need treatment, as shown by blood counts or an enlarged spleen

• Do not have an uncontrolled infection, heart or lung problems, or another cancer that needs treatment

• Have not received any treatment in the 4 weeks before the study begins

• Meet the study’s other lab and health requirements.

Who to contact about this trial:

Holly M Eager, R.N.; (240) 858-7229; holly.eager@nih.gov

…

Phase I Study of Anti-CD22 Chimeric Receptor T-Cells in patients with relapsed/refractory Hairy Cell Leukemia and Variant

Learn more about this clinical trial. (link to trial here)

What is the primary objective of this clinical trial?

To see if anti-CD22 CAR T-cells are safe and effective for people with HCL or HCLv after they have received a treatment regimen of cyclophosphamide and fludarabine.

CAR (Chimeric Antigen Receptor) T-cell therapy is a type of cancer treatment in which a person’s T cells (a type of immune cell) are changed in a laboratory to recognize and attack cancer cells. 

You may be able to join this trial if you:

• Have HCL or HCLv

• Have previously received treatment or been ineligible for: 1) Chemotherapy combined with Rituximab, 2) moxetumomab pasudotox, and/or 3) a BRAF inhibitor such as Vemurafenib.

• Need treatment

• Meet the study’s other lab and health requirements.

Who to contact about this trial:

This study has one location.

Olena Sierra: (240) 858-3185 or olena.sierraortiz@nih.gov

These studies do not include any treatments or medications. Instead, people with HCL and/or HCLv can help research by donating blood, bone marrow, or other samples. Researchers use these samples to learn more about the disease.

Collection of Human Samples to Study HCL and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Learn more about this trial. (link to trial here)

What are the primary objectives of this study?

To study HCL and how the disease compares with other disorders.

To collect a variety of clinical samples, including blood, urine, lymph samples, and other tissues, in order to study the samples and develop new treatments for HCL.  Individuals who have HCL will be asked to provide blood, bone marrow, urine, and tumor tissue samples as requested by the researchers. Healthy volunteers will provide only blood and urine samples.

No treatment will be given as part of this study.

You may be able to join this trial if you:

• Have HCL or HCLv

Who to contact about this study:

Julie C Feurtado, R.N.

(301) 480-6186 or julie.feurtado@nih.gov

…

Decoding the Extracellular Vesicles-Driven Crosstalk in Hairy Cell Leukemia

Learn more about this study. (link to study here)

What are the primary objectives of this study?

To better understand how extracellular vesicles - small particles released by cells - may contribute to the development and progression of HCL.

To study the communication between HCL cells and their surrounding environment, Biomarkers that may help predict disease behavior, and Potential new targets for future treatments.

Participants agree to provide samples that researchers use to investigate the biology of HCL. No experimental treatment is administered as part of the study.

You may be able to join this trial if you:

• Have HCL

• Are willing to provide blood and/or biological samples for research 

Who to contact about this study:

Name: Lucia Catani, PhD

Phone Number: +390512143837

Email: lucia.catani@unibo.it

Hairy Cell Leukemia is a rare disease and patients receive care from different doctors around the world. This makes it challenging for researchers to identify patterns, study unanswered questions, and develop more effective treatments.

Every piece of information collected for the registry strengthens research to improve diagnosis, treatment, and quality of life for people with HCL and HCL variants.

FOR MORE INFORMATION >> Click here (link to registry page)

Registry team contact information:

Phone: (614) 685-0635 Email: HCLRegistry@osumc.edu

Registry | ClinicalTrials.gov

Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients

Learn more about this trial. (link to trial here)

What are the primary objectives of this study?

To better understand the factors that influence a person's decision to participate in, discontinue, or rejoin a clinical trial for hairy cell leukemia.

Researchers hope to learn more about:

• Barriers to clinical trial participation

• Patient experiences during clinical trials

• Factors that affect enrollment decisions

• Ways to improve access to future clinical trials

This is a survey-based observational study. No treatment is provided as part of the study.

You may be able to join this trial if you:

• Have a diagnosis of hairy cell leukemia

• Have experience with, or have considered, participation in a clinical trial

• Are willing to complete study questionnaires or interviews

Who to contact about this study:

Michael B. Gill

Email: michael@powerlifesciences.com